ArticleEJNMMI research2026
FAPI PET/CT shows favorable potential for the evaluation of gallbladder cancer: a prospective study comparing [
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAccurate staging of gallbladder cancer (GBC) is crucial for treatment planning. [18F]FDG PET/CT is limited in evaluating GBC due to high liver background signal and difficulty distinguishing inflammatory from malignant lesions. [68Ga]Ga-FAPI-04 PET/CT offers high tumor uptake and tumor-background contrast, demonstrating significant value in assessing multiple tumor types. This study aimed to investigate the value and the impact on clinical staging management of [68Ga]Ga-FAPI-04 comparing with [18F]FDG PET/CT in patients with gallbladder cancer.
methodsThis prospective study included patients diagnosed with primary or recurrent gallbladder cancer based on ultrasound, MRI, and PET/CT evaluations. All patients underwent two scans with [68Ga]Ga-FAPI-04 and [18F]FDG PET/CT within one week. The study compared the detection capabilities and uptake (SUVmax and TBR) differences of both tracers in primary tumors, distant metastases, lymph nodes, and peritoneal metastases.
resultsThis study included 22 patients (age: 60.18 ± 9.53; 11 male, 11 female). [68Ga]Ga-FAPI-04 and [18F]FDG demonstrated comparable detection rates and maximum standardized uptake values (SUVmax) for primary gallbladder cancer lesions. However, [68Ga]Ga-FAPI-04 demonstrated significantly higher tumor-to-background ratios (TBR) in primary tumors (15.97 ± 9.70 vs. 5.96 ± 3.14, 95%CI [4.78,15.23], p=0.001). Higher detection rates (100% vs. 80%; 99% vs. 94%, respectively) and maximum standardized uptake values were observed for [68Ga]Ga-FAPI-04 in distant metastases and lymph node metastases (distant metastases: 8.88[5.53, 11.83] vs. 5.34[3.35, 9.80], 95%CI [1.93,4.25], p<0.001; lymph node metastasis: 8.85 [6.58, 11.20] vs. 6.00 [4.24, 8.03], 95%CI [2.44,3.43], p<0.001) and TBR values (distant metastasis: 11.18 [5.64, 14.97] vs. 6.11 [3.48, 12.75], 95%CI [7.46,11.15], p<0.001; Lymph node metastasis: 15.90 [10.31, 20.41] vs. 9.96 [6.09, 14.37], 95%CI [6.19,8.43], p<0.001). Additionally, [68Ga]Ga-FAPI-04 detected lesions in peritoneal involvement with higher SUVmax values. Ultimately, two patients had their staging upgraded based on [68Ga]Ga-FAPI-04 results, while two others had their staging downgraded.
conclusions[68Ga]Ga-FAPI-04 outperformed [¹⁸F]FDG in detecting primary gallbladder cancer tumors, distant metastases, lymph node metastases, and peritoneal metastases, demonstrating higher SUVmax values and TBR ratios. Additionally, [68Ga]Ga-FAPI-04 shows promise in staging gallbladder cancer and selecting patients for radionuclide-targeted therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.